LncRNA KCNQ1OT1 Promotes Proliferation and Invasion of Glioma Cells by Targeting the MiR‑375/YAP Pathway

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2020 Oct 30

PMID 33125099

Citations 8

Authors

Panfeng Ding

Bo Liang

Jixin Shou

Xinjun Wang

Affiliations

Soon will be listed here.

Abstract

The long non‑coding RNA KCNQ1OT1 is generally recognized as an oncogenic molecule in several human malignant tumors. However, to the best of our knowledge, the role of KCNQ1OT1 in glioma has not been fully investigated. The current study aimed to probe the biological function of KCNQ1OT1 in human glioma cell lines and its mechanisms. The glioma cell lines U251 and U87‑MG were used as cell models. Cell proliferation and apoptosis assays were used to measure the effects of different treatments on survival, and reverse transcription‑quantitative PCR and western blotting were used to investigate the expression profiles of key molecules. Migration and invasion assays were conducted to reveal the biological features of glioma cells. The results indicated that KCNQ1OT1 was upregulated in glioma tissues compared with adjacent tissues, which was associated with poor prognosis. Additionally, knockdown of KCNQ1OT1 in U251 and U87‑MG cells inhibited cell proliferation, migration and invasion, but had no effect on apoptosis. The effects of KCNQ1OT1 on migration and invasion were partially attributed to enhanced Yes‑associated protein (YAP) expression levels and epithelial‑mesenchymal transition (EMT) signaling. Furthermore, microRNA (miR)‑375 functioned as a link between KCNQ1OT1 and YAP in regulating cell proliferation. Finally, the KCNQ1OT1/miR‑375/YAP axis modulated cell proliferation and cell fate by affecting the modulated YAP‑mediated EMT signaling. In conclusion, the KCNQ1OT1/miR‑375/YAP axis modulated migration and invasion of glioma cells by affecting EMT signaling; thus, targeting KCNQ1OT1 may represent a promising strategy in glioma therapeutics.

Citing Articles

Nanoplatelets modified with RVG for targeted delivery of miR-375 and temozolomide to enhance gliomas therapy.

Yang T, Zhang N, Liu Y, Yang R, Wei Z, Liu F J Nanobiotechnology. 2024; 22(1):623.

PMID: 39402578 PMC: 11476726. DOI: 10.1186/s12951-024-02895-6.

Regulation of EMT Markers, Extracellular Matrix, and Associated Signalling Pathways by Long Non-Coding RNAs in Glioblastoma Mesenchymal Transition: A Scoping Review.

Leung D, Phon B, Sivalingam M, Radhakrishnan A, Kamarudin M Biology (Basel). 2023; 12(6).

PMID: 37372103 PMC: 10294841. DOI: 10.3390/biology12060818.

LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter.

He S, Chen Y, Chen Q, Tian Q, Yi S Mol Med. 2022; 28(1):112.

PMID: 36100884 PMC: 9469603. DOI: 10.1186/s10020-022-00521-5.

Research Progress on the Regulation Mechanism of Key Signal Pathways Affecting the Prognosis of Glioma.

Wu H, Wei M, Li Y, Ma Q, Zhang H Front Mol Neurosci. 2022; 15:910543.

PMID: 35935338 PMC: 9354928. DOI: 10.3389/fnmol.2022.910543.

The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.

Zhang Y, Wang Y, Ji H, Ding J, Wang K J Exp Clin Cancer Res. 2022; 41(1):202.

PMID: 35701841 PMC: 9199231. DOI: 10.1186/s13046-022-02403-4.

References

Meng X, Deng Y, Lv Z, Liu C, Guo Z, Li Y . LncRNA SNHG5 Promotes Proliferation of Glioma by Regulating miR-205-5p/ZEB2 Axis. Onco Targets Ther. 2020; 12:11487-11496. PMC: 6939796. DOI: 10.2147/OTT.S228439. View

Mao H, LeBrun D, Yang J, Zhu V, Li M . Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012; 30(1):48-56. PMC: 3799884. DOI: 10.3109/07357907.2011.630050. View

Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C . The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-72. DOI: 10.1016/j.cell.2011.09.048. View

Xin S, Huang K, Zhu X . Non-coding RNAs: Regulators of glioma cell epithelial-mesenchymal transformation. Pathol Res Pract. 2019; 215(9):152539. DOI: 10.1016/j.prp.2019.152539. View

Rivas S, Anton I, Wandosell F . WIP-YAP/TAZ as A New Pro-Oncogenic Pathway in Glioma. Cancers (Basel). 2018; 10(6). PMC: 6024887. DOI: 10.3390/cancers10060191. View

Nawaz Z, Patil V, Arora A, Hegde A, Arivazhagan A, Santosh V . Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription. Sci Rep. 2016; 6:27753. PMC: 4904208. DOI: 10.1038/srep27753. View

Reggiani F, Gobbi G, Ciarrocchi A, Ambrosetti D, Sancisi V . Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020; 1873(1):188341. DOI: 10.1016/j.bbcan.2020.188341. View

Spinelli G, Miele E, Lo Russo G, Miscusi M, Codacci-Pisanelli G, Petrozza V . Chemotherapy and target therapy in the management of adult high- grade gliomas. Curr Cancer Drug Targets. 2012; 12(8):1016-31. DOI: 10.2174/156800912803251207. View

Wang J, Su H, Zhao H, Chen Z, To S . Progress in the application of molecular biomarkers in gliomas. Biochem Biophys Res Commun. 2015; 465(1):1-4. DOI: 10.1016/j.bbrc.2015.07.148. View

10.

Li C, Zheng H, Hou W, Bao H, Xiong J, Che W . Long non-coding RNA linc00645 promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-205-3p-ZEB1 axis in glioma. Cell Death Dis. 2019; 10(10):717. PMC: 6763487. DOI: 10.1038/s41419-019-1948-8. View

11.

Luo Z, Jin H . Effects of LncRNA KCNQ1OT1 on proliferation and migration of ovarian cancer cells by Wnt/β-catenin. Eur Rev Med Pharmacol Sci. 2019; 23(20):8788-8794. DOI: 10.26355/eurrev_201910_19273. View

12.

Wang J, Zhang H, Situ J, Li M, Sun H . KCNQ1OT1 aggravates cell proliferation and migration in bladder cancer through modulating miR-145-5p/PCBP2 axis. Cancer Cell Int. 2019; 19:325. PMC: 6889643. DOI: 10.1186/s12935-019-1039-z. View

13.

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

14.

Li P, Wang X, Shan Q, Wu Y, Wang Z . Evaluation of TAZ expression and its effect on tumor invasion and metastasis in human glioma. Asian Pac J Trop Med. 2014; 7(10):757-60. DOI: 10.1016/S1995-7645(14)60131-0. View

15.

Zhang D, Lu Z, Man J, Cui K, Fu X, Yu L . Wnt-3a alleviates neuroinflammation after ischemic stroke by modulating the responses of microglia/macrophages and astrocytes. Int Immunopharmacol. 2019; 75:105760. DOI: 10.1016/j.intimp.2019.105760. View

16.

Lee H, Hwang S, Kim H, Shin C, Choi K, Joung J . Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta. 2016; 1859(4):599-611. DOI: 10.1016/j.bbagrm.2016.02.010. View

17.

Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E . Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2013; 50(4):301-21. DOI: 10.5114/fn.2012.32361. View

18.

Li Y, Li C, Li D, Yang L, Jin J, Zhang B . lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther. 2019; 12:2649-2660. PMC: 6462170. DOI: 10.2147/OTT.S188054. View

19.

Li J, Li Z, Wu Y, Wang Y, Wang D, Zhang W . The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma. Cell Death Dis. 2019; 10(8):603. PMC: 6689034. DOI: 10.1038/s41419-019-1838-0. View

20.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View